• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    575.84 -5.90 (-1.01%)
    Streaming Delayed Price Updated: 2:34 PM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 130,031
    Open 581.17
    Bid (Size) 575.64 (80)
    Ask (Size) 576.57 (40)
    Prev. Close 581.74
    Today's Range 574.84 - 584.71
    52wk Range 272.12 - 609.35
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
    United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu... 
    Via StockStory
    Topics Earnings
    News headline image
    United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire

    Performance

    YTD
    +15.9%
    +15.9%
    1 Month
    -0.3%
    -0.3%
    3 Month
    +21.7%
    +21.7%
    6 Month
    +25.4%
    +25.4%
    1 Year
    +85.3%
    +85.3%

    More News

    Read More
    News headline image
    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
    Via StockStory
    United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗
    Via Chartmill
    United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
    Via Chartmill
    News headline image
    UTHR Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Reports First Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
    From MannKind
    Via GlobeNewswire
    News headline image
    United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Reasons Investors Love United Therapeutics (UTHR)
    Via StockStory
    Topics Stocks
    News headline image
    United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Market-Beating Stocks for Long-Term Investors
    Via StockStory
    Topics Energy
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    Via MarketMinute
    Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗
    Via Chartmill
    Topics Economy
    News headline image
    Why United Therapeutics (UTHR) Stock Is Up Today
    Via StockStory
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
    Via StockStory

    Frequently Asked Questions

    Is United Therapeutics Corporation - Common Stock publicly traded?
    Yes, United Therapeutics Corporation - Common Stock is publicly traded.
    What exchange does United Therapeutics Corporation - Common Stock trade on?
    United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for United Therapeutics Corporation - Common Stock?
    The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
    What is the current price of United Therapeutics Corporation - Common Stock?
    The current price of United Therapeutics Corporation - Common Stock is 575.84
    When was United Therapeutics Corporation - Common Stock last traded?
    The last trade of United Therapeutics Corporation - Common Stock was at 05/13/26 02:34 PM ET
    What is the market capitalization of United Therapeutics Corporation - Common Stock?
    The market capitalization of United Therapeutics Corporation - Common Stock is 25.85B
    How many shares of United Therapeutics Corporation - Common Stock are outstanding?
    United Therapeutics Corporation - Common Stock has 26B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.